Chinese NMPA approves Bayer’s oral ARi Nubeqa in combo with ADT for use in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, February 4, 2026, 14:00 ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

Recently, the research team led by Professor Jun Pang from the Department of Urology at The Seventh Affiliated Hospital of Sun Yat-sen University ...

This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: Testosterone’s reputation for causing anger and aggression ...

Prostate cancer (PCa) remains a significant global health challenge, with rising morbidity rates and poor prognosis associated with advanced stages ...

India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved a wide range of recombinant DNA (r-DNA)-origin drugs and biologics for manufacture ...